Amarin shares represent a "compelling investment opportunity" ahead of data for the company's Reduce-It study before the end of Q3, Cantor Fitzgerald analyst Louise Chen wrote Friday in a research note to investors. She expects the data to be positive. Amarin recently raised $70M and could raise up to another $10.5M gross, if overallotment is exercised, ahead of the data readout which removes a financing overhang and accelerates the company's plan to expand its sales and promotion of Vascepa, Chen argues. She keeps an Overweight rating on the shares with a $10 price target.